A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-07-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12943-022-01617-6 |